Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex

A. Fogarasi, L. De Waele, G. Bartalini, S. Jozwiak, N. Laforgia, H. Verhelst, B. Petrak, JM. Pedespan, O. Witt, R. Castellana, S. Crippa, G. Gislimberti, Z. Gyorsok,

. 2016 ; 16 (-) : 126. [pub] 20160808

Language English Country England, Great Britain

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17000234

BACKGROUND: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to be effective and safe in the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC). The Everolimus For Fast Expanded aCcess in TSC SEGA (EFFECTS) study was designed to provide everolimus access to patients with SEGA associated with TSC and to mainly assess the safety and also efficacy of everolimus in a real-world setting. METHODS: EFFECTS was a phase 3b, open-label, noncomparative, multicenter, expanded access study. Eligible patients were ≥ 3 years of age, with a definite diagnosis of TSC, and with at least one SEGA lesion identified by MRI or CT scan. Patients received once daily everolimus (dose adjusted to attain a trough level of 5-15 ng/mL). Safety evaluation was the primary objective and included collection of adverse events (AEs) and serious AEs, with their severity and relationship to everolimus. Efficacy evaluation, which was the secondary objective, was based on the best overall response as per medical judgment. RESULTS: Of the 120 patients enrolled, 100 (83.3%) completed the study. Median age of patients was 11 years (range, 1-47). Median daily dose of everolimus was 5.82 mg (range, 2.0-11.8). Median duration of exposure was 56.5 weeks (range, 0.3-130). The overall incidence of AEs was 74.2%. Aphthous stomatitis (18 [15.0%]), pyrexia (18 [15.0%]), bronchitis (11 [9.2%]), and stomatitis (10 [8.3%]) were the most common AEs reported. Overall, 25 patients had grade 3 AEs; most frequent was stomatitis (4 [3.3%]). Grade 4 AEs were reported in three (2.5%) patients. A total of 62 (51.7%) patients had suspected drug-related AEs, of which 15 (12.5%) were of grade 3 or 4. In eight (6.7%) patients, AEs led to drug discontinuation. With regard to efficacy, 81 (67.5%) patients had a partial response, 35 (29.2%) had a stable disease, and one (0.8%) had progressive disease. The response was unknown in three (2.5%) patients. CONCLUSION: This study confirms the acceptable safety profile of everolimus in patients with SEGA associated with TSC in a real-world setting. The results further support the efficacy of everolimus in the treatment of SEGA associated with TSC. (EudraCT: 2010-022583-13).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000234
003      
CZ-PrNML
005      
20170112123502.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12883-016-0658-4 $2 doi
024    7_
$a 10.1186/s12883-016-0658-4 $2 doi
035    __
$a (PubMed)27502586
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Fogarasi, Andras $u Neurology Department, Bethesda Children's Hospital, Bethesda Street 3, H-1146, Budapest, Hungary. fog.andras@gmail.com.
245    10
$a EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex / $c A. Fogarasi, L. De Waele, G. Bartalini, S. Jozwiak, N. Laforgia, H. Verhelst, B. Petrak, JM. Pedespan, O. Witt, R. Castellana, S. Crippa, G. Gislimberti, Z. Gyorsok,
520    9_
$a BACKGROUND: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to be effective and safe in the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC). The Everolimus For Fast Expanded aCcess in TSC SEGA (EFFECTS) study was designed to provide everolimus access to patients with SEGA associated with TSC and to mainly assess the safety and also efficacy of everolimus in a real-world setting. METHODS: EFFECTS was a phase 3b, open-label, noncomparative, multicenter, expanded access study. Eligible patients were ≥ 3 years of age, with a definite diagnosis of TSC, and with at least one SEGA lesion identified by MRI or CT scan. Patients received once daily everolimus (dose adjusted to attain a trough level of 5-15 ng/mL). Safety evaluation was the primary objective and included collection of adverse events (AEs) and serious AEs, with their severity and relationship to everolimus. Efficacy evaluation, which was the secondary objective, was based on the best overall response as per medical judgment. RESULTS: Of the 120 patients enrolled, 100 (83.3%) completed the study. Median age of patients was 11 years (range, 1-47). Median daily dose of everolimus was 5.82 mg (range, 2.0-11.8). Median duration of exposure was 56.5 weeks (range, 0.3-130). The overall incidence of AEs was 74.2%. Aphthous stomatitis (18 [15.0%]), pyrexia (18 [15.0%]), bronchitis (11 [9.2%]), and stomatitis (10 [8.3%]) were the most common AEs reported. Overall, 25 patients had grade 3 AEs; most frequent was stomatitis (4 [3.3%]). Grade 4 AEs were reported in three (2.5%) patients. A total of 62 (51.7%) patients had suspected drug-related AEs, of which 15 (12.5%) were of grade 3 or 4. In eight (6.7%) patients, AEs led to drug discontinuation. With regard to efficacy, 81 (67.5%) patients had a partial response, 35 (29.2%) had a stable disease, and one (0.8%) had progressive disease. The response was unknown in three (2.5%) patients. CONCLUSION: This study confirms the acceptable safety profile of everolimus in patients with SEGA associated with TSC in a real-world setting. The results further support the efficacy of everolimus in the treatment of SEGA associated with TSC. (EudraCT: 2010-022583-13).
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a protinádorové látky $x škodlivé účinky $x terapeutické užití $7 D000970
650    _2
$a astrocytom $x farmakoterapie $7 D001254
650    _2
$a nádory mozku $x farmakoterapie $7 D001932
650    _2
$a bronchitida $x chemicky indukované $7 D001991
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a progrese nemoci $7 D018450
650    _2
$a everolimus $x škodlivé účinky $x terapeutické užití $7 D000068338
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a horečka $x chemicky indukované $7 D005334
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a indukce remise $7 D012074
650    _2
$a bezpečnost $7 D012449
650    _2
$a stomatitida $x chemicky indukované $7 D013280
650    _2
$a aftózní stomatitida $x chemicky indukované $7 D013281
650    _2
$a výsledek terapie $7 D016896
650    _2
$a tuberózní skleróza $x farmakoterapie $7 D014402
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a De Waele, Liesbeth $u Gasthuisberg University Hospitals Leuven, Leuven, Belgium.
700    1_
$a Bartalini, Gabriella $u Pediatric Unit, University Hospital, Siena, Italy.
700    1_
$a Jozwiak, Sergiusz $u Children's Memorial Health Institute, Warsaw, Poland. Department of Pediatric Neurology, Medical University of Warsaw, Warsaw, Poland.
700    1_
$a Laforgia, Nicola $u Neonatology and NICU Section, DIMO, University of Bari, Bari, Italy.
700    1_
$a Verhelst, Helene $u Ghent University Hospital, Ghent, Belgium.
700    1_
$a Petrak, Borivoj $u Motol University Hospital, Prague, Czech Republic.
700    1_
$a Pedespan, Jean-Michel $u CHU Pellegrin-Hôpital des Enfants, Bordeaux, France.
700    1_
$a Witt, Olaf $u German Cancer Research Center and Section of Pediatric Brain Tumors, University Hospital, Heidelberg, Germany.
700    1_
$a Castellana, Ramon $u Novartis Farmacéutica SA, Barcelona, Spain.
700    1_
$a Crippa, Stefania $u Novartis Farma S.p.A., Origgio, Italy.
700    1_
$a Gislimberti, Gabriella $u Novartis Farma S.p.A., Origgio, Italy.
700    1_
$a Gyorsok, Zsuzsanna $u Neurology Department, Bethesda Children's Hospital, Bethesda Street 3, H-1146, Budapest, Hungary. National Institute of Neurosciences, Budapest, Hungary.
773    0_
$w MED00008195 $t BMC neurology $x 1471-2377 $g Roč. 16, č. - (2016), s. 126
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27502586 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170112123601 $b ABA008
999    __
$a ok $b bmc $g 1179374 $s 960801
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 16 $c - $d 126 $e 20160808 $i 1471-2377 $m BMC neurology $n BMC Neurol $x MED00008195
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options